单药治疗-话题@MedSci

#单药治疗#

130篇内容 | 3974人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2264231, encodeId=9a192264231e4, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a> <a href='/topic/show?id=94e3126e4461' target=_blank style='color:#2F92EE;'>#英克司兰钠#</a>, objectTitle=他汀不耐受者福音！JACC：3个月一针，新药单用降脂达46%, objectType=article, longId=874620, objectId=ee698e4620bb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240714/1720959810929_5579292.jpg, objectUrl=/article/show_article.do?id=ee698e4620bb, replyNumber=0, likeNumber=29, createdTime=2025-05-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=ee698e4620bb, moduleTitle=他汀不耐受者福音！JACC：3个月一针，新药单用降脂达46%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee698e4620bb)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2189837, encodeId=d883218983e6c, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a> <a href='/topic/show?id=7609111649d5' target=_blank style='color:#2F92EE;'>#依沃西单抗#</a> <a href='/topic/show?id=ad53111650e9' target=_blank style='color:#2F92EE;'>#晚期NSCLCL#</a>, objectTitle=J Thorac Oncol：依沃西单抗单药治疗晚期NSCLC的I期临床试验分析, objectType=article, longId=815047, objectId=ed7f81504e5f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240227/1709042358268_6145188.png, objectUrl=/article/show_article.do?id=ed7f81504e5f, replyNumber=0, likeNumber=112, createdTime=2024-02-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ed7f81504e5f, moduleTitle=J Thorac Oncol：依沃西单抗单药治疗晚期NSCLC的I期临床试验分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed7f81504e5f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1687798, encodeId=aa22168e79822, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=DRCP：格列美脲/二甲双胍固定联合剂与单药治疗2型糖尿病患者的比较研究, objectType=article, longId=738900, objectId=a718e389006c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a718e389006c, replyNumber=0, likeNumber=80, createdTime=2023-01-04, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a718e389006c, moduleTitle=DRCP：格列美脲/二甲双胍固定联合剂与单药治疗2型糖尿病患者的比较研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a718e389006c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687795, encodeId=3d10168e79526, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=Dermatol Ther：阿普斯特单药治疗是中重度斑块状银屑病的有效治疗方案, objectType=article, longId=733991, objectId=cffee33991ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cffee33991ac, replyNumber=0, likeNumber=117, createdTime=2022-12-06, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cffee33991ac, moduleTitle=Dermatol Ther：阿普斯特单药治疗是中重度斑块状银屑病的有效治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cffee33991ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687791, encodeId=c082168e79146, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效, objectType=article, longId=727599, objectId=801de275994a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=801de275994a, replyNumber=0, likeNumber=112, createdTime=2022-12-14, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=801de275994a, moduleTitle=J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=801de275994a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687790, encodeId=65a5168e7907c, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=“神药”成癌症免疫治疗理想拍档？他汀类或为抗PD-1单药治疗的非小细胞肺癌患者带来生存获益！, objectType=article, longId=726547, objectId=916ae26547dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=916ae26547dc, replyNumber=0, likeNumber=112, createdTime=2023-02-09, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=916ae26547dc, moduleTitle=“神药”成癌症免疫治疗理想拍档？他汀类或为抗PD-1单药治疗的非小细胞肺癌患者带来生存获益！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=916ae26547dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687796, encodeId=1b4b168e79689, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=Lancet：他汀+依折麦布联合治疗vs高强度他汀单药治疗在ASCVD中的疗效更佳！, objectType=article, longId=734082, objectId=2b97e3408225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b97e3408225, replyNumber=0, likeNumber=119, createdTime=2022-08-16, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b97e3408225, moduleTitle=Lancet：他汀+依折麦布联合治疗vs高强度他汀单药治疗在ASCVD中的疗效更佳！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b97e3408225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687793, encodeId=3d95168e793a4, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=JAMA Oncol：恩杂鲁胺单药治疗可明显降低积极监测的中低危前列腺癌的进展率, objectType=article, longId=730184, objectId=4ac6e301848e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ac6e301848e, replyNumber=0, likeNumber=107, createdTime=2023-03-30, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ac6e301848e, moduleTitle=JAMA Oncol：恩杂鲁胺单药治疗可明显降低积极监测的中低危前列腺癌的进展率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ac6e301848e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687797, encodeId=3b81168e79751, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=【每日播报】-对于新诊断T2DM患者，磺脲类各药物单药治疗疗效, objectType=article, longId=737874, objectId=5b10e378749f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b10e378749f, replyNumber=0, likeNumber=90, createdTime=2023-03-22, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b10e378749f, moduleTitle=【每日播报】-对于新诊断T2DM患者，磺脲类各药物单药治疗疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b10e378749f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687777, encodeId=772d168e777b3, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=Clin Cancer Res：Cabozantinib（卡博替尼）单药治疗难治性软组织肉瘤(STS)的疗效和安全性, objectType=article, longId=291974, objectId=52c52919e488, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52c52919e488, replyNumber=0, likeNumber=106, createdTime=2022-08-23, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52c52919e488, moduleTitle=Clin Cancer Res：Cabozantinib（卡博替尼）单药治疗难治性软组织肉瘤(STS)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52c52919e488)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687785, encodeId=aaae168e78591, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效, objectType=article, longId=723401, objectId=df51e23401fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df51e23401fa, replyNumber=0, likeNumber=120, createdTime=2022-07-14, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df51e23401fa, moduleTitle=Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df51e23401fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687783, encodeId=75db168e78399, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, objectType=article, longId=301707, objectId=d31c301e07bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d31c301e07bd, replyNumber=0, likeNumber=119, createdTime=2022-12-16, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d31c301e07bd, moduleTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d31c301e07bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687794, encodeId=d51d168e794b4, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=Ann Hematol：吉列替尼单药治疗复发/难治性 FLT3 突变急性髓细胞白血病的真实世界研究, objectType=article, longId=730781, objectId=f847e307815e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f847e307815e, replyNumber=0, likeNumber=92, createdTime=2023-03-25, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f847e307815e, moduleTitle=Ann Hematol：吉列替尼单药治疗复发/难治性 FLT3 突变急性髓细胞白血病的真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f847e307815e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687784, encodeId=c66e168e7843c, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=Rheumatology：Apremilast单药治疗DMARD无效的活动性银屑病关节炎的长期疗效, objectType=article, longId=301742, objectId=ea63301e42f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea63301e42f2, replyNumber=0, likeNumber=128, createdTime=2023-02-05, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea63301e42f2, moduleTitle=Rheumatology：Apremilast单药治疗DMARD无效的活动性银屑病关节炎的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea63301e42f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687769, encodeId=0042168e76916, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=Eur Heart J：接受PCI的高出血风险患者替格瑞洛单药治疗效果分析, objectType=article, longId=218975, objectId=c8aa2189e5f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8aa2189e5f1, replyNumber=0, likeNumber=102, createdTime=2022-05-02, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8aa2189e5f1, moduleTitle=Eur Heart J：接受PCI的高出血风险患者替格瑞洛单药治疗效果分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8aa2189e5f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687773, encodeId=8f36168e77342, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=Clin Cancer Res：多受体酪氨酸激酶抑制剂卡博替尼单药治疗晚期软组织肉瘤的效果, objectType=article, longId=220644, objectId=1bac22064495, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bac22064495, replyNumber=0, likeNumber=106, createdTime=2022-09-28, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bac22064495, moduleTitle=Clin Cancer Res：多受体酪氨酸激酶抑制剂卡博替尼单药治疗晚期软组织肉瘤的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bac22064495)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687792, encodeId=b3fd168e792ca, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=Dig Dis Sci：硫嘌呤单药治疗可有效维持轻中度炎症性肠病患者的临床缓解状态, objectType=article, longId=724927, objectId=7a46e249275e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a46e249275e, replyNumber=0, likeNumber=97, createdTime=2022-05-14, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a46e249275e, moduleTitle=Dig Dis Sci：硫嘌呤单药治疗可有效维持轻中度炎症性肠病患者的临床缓解状态, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a46e249275e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687787, encodeId=7240168e787bd, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=Clin Cancer Res：Pembrolizumab单药治疗晚期肝细胞癌的效果, objectType=article, longId=724681, objectId=ae69e2468173, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae69e2468173, replyNumber=0, likeNumber=112, createdTime=2022-05-08, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae69e2468173, moduleTitle=Clin Cancer Res：Pembrolizumab单药治疗晚期肝细胞癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae69e2468173)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687768, encodeId=cb49168e76830, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, objectType=article, longId=218739, objectId=cba7218e390b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cba7218e390b, replyNumber=0, likeNumber=160, createdTime=2022-02-20, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cba7218e390b, moduleTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cba7218e390b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687767, encodeId=0e06168e76769, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, objectTitle=HAEMATOLOGICA：接受阿卡拉布替尼单药治疗的慢性淋巴细胞白血病患者的心血管不良事件: 762例患者的汇总分析。, objectType=article, longId=218053, objectId=6f90218053de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f90218053de, replyNumber=0, likeNumber=93, createdTime=2022-03-19, rootId=0, userName=12498717m75(暂无昵称), userId=2bef28414326, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f90218053de, moduleTitle=HAEMATOLOGICA：接受阿卡拉布替尼单药治疗的慢性淋巴细胞白血病患者的心血管不良事件: 762例患者的汇总分析。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f90218053de)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

单药治疗

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#单药治疗# #英克司兰钠#

他汀不耐受者福音！JACC：3个月一针，新药单用降脂达46%

2025-05-09发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#单药治疗# #依沃西单抗# #晚期NSCLCL#

J Thorac Oncol：依沃西单抗单药治疗晚期NSCLC的I期临床试验分析

2024-02-28发表于上海

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

DRCP：格列美脲/二甲双胍固定联合剂与单药治疗2型糖尿病患者的比较研究

2023-01-04

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

Dermatol Ther：阿普斯特单药治疗是中重度斑块状银屑病的有效治疗方案

2022-12-06

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效

2022-12-14

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

“神药”成癌症免疫治疗理想拍档？他汀类或为抗PD-1单药治疗的非小细胞肺癌患者带来生存获益！

2023-02-09

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

Lancet：他汀+依折麦布联合治疗vs高强度他汀单药治疗在ASCVD中的疗效更佳！

2022-08-16

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

JAMA Oncol：恩杂鲁胺单药治疗可明显降低积极监测的中低危前列腺癌的进展率

2023-03-30

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

【每日播报】-对于新诊断T2DM患者，磺脲类各药物单药治疗疗效

2023-03-22

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

Clin Cancer Res：Cabozantinib（卡博替尼）单药治疗难治性软组织肉瘤(STS)的疗效和安全性

2022-08-23

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效

2022-07-14

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效

2022-12-16

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

Ann Hematol：吉列替尼单药治疗复发/难治性 FLT3 突变急性髓细胞白血病的真实世界研究

2023-03-25

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

Rheumatology：Apremilast单药治疗DMARD无效的活动性银屑病关节炎的长期疗效

2023-02-05

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

Eur Heart J：接受PCI的高出血风险患者替格瑞洛单药治疗效果分析

2022-05-02

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

Clin Cancer Res：多受体酪氨酸激酶抑制剂卡博替尼单药治疗晚期软组织肉瘤的效果

2022-09-28

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

Dig Dis Sci：硫嘌呤单药治疗可有效维持轻中度炎症性肠病患者的临床缓解状态

2022-05-14

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

Clin Cancer Res：Pembrolizumab单药治疗晚期肝细胞癌的效果

2022-05-08

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见

2022-02-20

12498717m75(暂无昵称) (审核中...)

前往app查看评论内容

#单药治疗#

HAEMATOLOGICA：接受阿卡拉布替尼单药治疗的慢性淋巴细胞白血病患者的心血管不良事件: 762例患者的汇总分析。

2022-03-19

科室
- - 订阅+
  - 更多科室
工具
服务